Noah Craft, MD
Dermatology · Torrance, CANPI 1750351193
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,064 of the $6,193 with a category attached, or 81.8%. Janssen Research & Development, LLC accounts for 93.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $5,909 and has fallen 97.5% since, to $146 in 2025.
Across 16 payments — averaging $387.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$6K
- Johnson & Johnson$93
- Sanofi$92
- Amgen$35
- Regeneron Healthcare Solutions, Inc.$35
- AbbVie$30
- plus $103 from 5 others
Across 7 payments — averaging $4300.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$30K
- Dexcom, Inc.$310
What the payments were for
- Consulting fees$5,06482%
- Travel & lodging$74112%
- Food & beverage$3005%
- Education$881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 3 | $5,805 |
| Johnson & Johnson | 2 | $93 |
| Sanofi | 3 | $92 |
| Amgen | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| AbbVie | 1 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Incyte Corporation | 1 | $13 |
How this compares
$6,193 in reported general payments places this provider in the 70th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 15 | $971 |
| Betamethasone Dipropionate | 12 | $457 |
| Triamcinolone Acetonide | 31 | $313 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Torrance
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.